axitinib

This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

The ATLAS study was testing whether VEGF inhibitor Inlyta (axitinib) given as an adjuvant treatment after surgery to remove the tumour could improve disease-free survival compared to placebo, but has

Latest news

Good NICE news for Pfizer, but Dendreon drug rejected

NICE has given a final recommendation to Pfizer's new kidney cancer pill Inlyta (axitinib) - but has rejected Dendreon's prostate cancer treatment Provenge (sipuleucel-T).
NICE backs Pfizer drug in kidney cancer

The National Institute for Health and Care Excellence (NICE), which provides healthcare guidance for the NHS, backed the use of Inlyta (axitinib) in advanced kidney cancer two years after turning down ... Although, this recommendation has not changed
Pfizer signs $2.85bn immuno-oncology alliance

Earlier this year, Pfizer signed an agreement with Merck &Co to test Keytruda alongside Xalkori (crizotinib) in patients with NSCLC, breast cancer and melanoma candidate palbociclib and Inlyta (axitinib) in patients
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Bosulif (bosutinib). Leukaemia (3 indications). Inlyta (axitinib). Renal cancer. Xalkori (crizotinib).
Pfizer and Merck expand anti-PD1 cancer alliance

types. The two companies are already testing the drug in combination with Pfizer's renal cell carcinoma therapy Inlyta (axitinib) and breast cancer and melanoma candidate palbociclib, a CDK inhibitor that

More from news
Approximately 7 fully matching, plus 27 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.
Oncology drugs under AMNOG

Pfizer’ s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Manager / Account Director: Great salary and bebefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Programme Executive: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Medical Writer: Great salary and bebefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager or AD - Medical Communications: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and benefits

Scientific Director: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor – Medical Education Agency – Bucks: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Subscribe to our email news alerts

PMHub

Add my company

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...